Amid negative news regarding stagnating booking growth and
saturated underlying markets for
), the launch of a new product by Epocrates, Inc., an
athenahealth subsidiary, should boost investor confidence in the
ATHENAHEALTH IN (ATHN): Free Stock Analysis
RESMED INC (RMD): Free Stock Analysis Report
STRAUMANN (SAUHF): Get Free Report
TRINITY BIOTECH (TRIB): Free Stock Analysis
To read this article on Zacks.com click here.
Epocrates has launched a new mobile application (app), "Epocrates
Bugs + Drugs", which combines cloud-based clinical data with a
user-friendly mobile interface. The app is designed to locate
local bacterial superbugs (bacteria that are resistant to
antibiotics) and assist physicians to timely prescribe
appropriate antibiotics. The much awaited "Epocrates Bugs +
Drugs" is now available for free for iOS 7 devices in the Apple
As per a report by Centers for Disease Control and Prevention
(CDC), more than 2 million individuals in the U.S. contract
drug-resistant infections such as E. coli and staph, out of which
around 23,000 people die annually. The new Bug + Drug offering
from ATHN brings caregivers one step closer to personalized
medicine, whereby doctors can identify common and uncommon bugs
in the communities where their patients live, and accordingly
prescribe the best treatment.
Using the abovementioned mobile app, physicians can easily access
athenahealth's large EHR database of 15 million patients on their
mobile phones. The real-time, geography-specific information
regarding superbugs prevalent in the location, where a particular
patient resides, is a significant advancement in the field of
clinical innovation and benefit the entire health system.
Recently, athenahealth entered into a partnership with NextGxDx
Inc., the comprehensive online marketplace for genetic testing,
to deliver an integrated platform that will help clinicians
improve genetic test ordering. The collaboration of the two
companies will enable ATHN's clinicians to avail genetic testing
through an integrated EHR platform.
Currently, athenahealth carries a Zacks Rank #5 (Strong Sell).
While we strongly recommend avoiding this stock, other
better-placed medical stocks that are worth a look include
Trinity Biotech plc
STRAUMANN HLD N AKT
). All these stocks carry a Zacks Rank #1 (Strong Buy).